Patient Preparation with Esomeprazole Is Comparable to Ranitidine in Meckel Diverticulum Scintigraphy

Tessa F. Ververs¹,², Anne-Fleur H. Lobbezoo³, Monique G. Hobbelink¹, and Arthur J. Braat¹

¹Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands; ²Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands; and ³Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands

To localize ectopic gastric mucosa in patients with unexplained gastrointestinal bleeding and diagnose a Meckel diverticulum, ⁹⁹ᵐTc-pertechnetate imaging is the standard procedure. H₂ inhibitor pretreatment enhances the sensitivity of the scan by reducing washout of ⁹⁹ᵐTc activity from the intestinal lumen. We aim to provide evidence of the effectiveness of the proton pump inhibitor esomeprazole as an ideal substitute for ranitidine. Methods: The scan quality for 142 patients who underwent a Meckel scan during a period of 10 y was evaluated. The patients were pretreated with ranitidine orally or intravenously before a switch to a proton pump inhibitor after ranitidine was no longer available. Good scan quality was characterized by the absence of ⁹⁹ᵐTc-pertechnetate activity in the gastrointestinal lumen. The effectiveness of esomeprazole to diminish ⁹⁹ᵐTc-pertechnetate release was compared with the standard treatment using ranitidine. Results: Pretreatment with intravenous esomeprazole resulted in 48% of scans with no ⁹⁹ᵐTc-pertechnetate release, 17% with release either in the intestine or in the duodenum, and 35% with ⁹⁹ᵐTc-pertechnetate activity both in the intestine and in the duodenum. Evaluation of scans obtained after oral ranitidine and intravenous ranitidine showed absence of activity in both intestine and duodenum in 16% and 23% of the cases, respectively. The indicated time to administer esomeprazole before starting the scan procedure was 30 min, but a delay of 15 min did not negatively influence the scan quality. Conclusion: This study confirms that esomeprazole, 40 mg, when administered intravenously 30 min before a Meckel scan, enhances the scan quality comparably to ranitidine. This procedure can be incorporated into protocols.

Key Words: Meckel diverticulum; ⁹⁹ᵐTc-pertechnetate scintigraphy; ectopic gastric mucosa; esomeprazole; ranitidine

J Nucl Med Technol 2023; 51:211–214
DOI: 10.2967/jnmt.123.265558

M eckel diverticulum, the most common gastrointestinal congenital anomaly, is located predominantly in the lower part of the ileum. The condition occurs in 2%–3% of the population (1). Although most cases of Meckel diverticulum remain asymptomatic, 15% lead to complications including hemorrhage, diverticulitis, obstruction, or perforation (1). Hemorrhage is usually caused by ulceration of the bowel wall because of ectopic gastric mucosa in the Meckel diverticulum and requires surgical intervention (1,2).

The specificity of a Meckel scan in detecting ectopic gastric mucosa is well established (95%–100%). Sensitivity may vary and depends partly on the amount of ectopic tissue (3). Excessive excretion of ⁹⁹ᵐTc-pertechnetate from the gastric mucosal tissue in the gastrointestinal lumen may interfere with the detection of ectopic gastric mucosa. H₂ receptor antagonists increase the sensitivity of the Meckel scan by preventing release of ⁹⁹ᵐTc-pertechnetate from mucous cells in the stomach and ectopic gastric mucosa and therefore enhancing visualization of anomalies (3,4). It is thought that inhibition of acid secretion inhibits the release of radioactivity in the lumen as well, resulting in reduced risk of a false-negative or false-positive diagnosis (4). The use of H₂ antagonists such as cimetidine and ranitidine was included in the Society of Nuclear Medicine and Molecular Imaging and European Association of Nuclear Medicine practice guideline for Meckel diverticulum scintigraphy (5).

However, this practice had to be altered when the supply of H₂ antagonists ran dry after the recall of ranitidine from the European market in October 2019 in response to possible contamination with N-nitrosodimethylamine (6,7). With the assumption that any systemic antacid could serve as an alternative, proton pump inhibitors (PPIs) were proposed (5). Since esomeprazole is widely used in standard care for numerous conditions, we considered this PPI a practical alternative to ranitidine (8). Moreover its favorable pharmacokinetics and rapid onset after intravenous injection make esomeprazole an ideal candidate to replace H₂ inhibitors (8–10). However, the effectiveness of esomeprazole in enhancing Meckel scan quality has yet to be established. The aim of this study was to determine whether esomeprazole is as effective as ranitidine when used in the prescan procedure.

MATERIALS AND METHODS

All patients who had a Meckel scan in our hospital between January 2012 and September 2022 were retrospectively included. Demographic data, including age at presentation and sex, were recorded, as well as details on prescan medication (time between administration of the antacid and the scan, interfering medication,
Activity in the intestine). The quality was considered good if no intestinal activity visualization (absence, activity in the duodenum, or patient obscured by the bladder (2 min/image). If it was difficult to distinguish activity in the ureter from a Meckel diverticulum, furosemide could be administered. A SPECT/CT scan could be added at the discretion of the nuclear medicine physician on call, to specify the anatomic localization of a Meckel diverticulum.

All positive Meckel scans were followed by surgical resection. To analyze the difference in scan quality between the esomeprazole pretreated group and the 2 ranitidine groups, the \( \chi^2 \) test was used, with a \( P \) value of less than 0.05 being considered a significant difference.

RESULTS

Between January 2012 and September 2022, 183 patients had a Meckel scan. Scans containing missing data regarding the prescan procedure were excluded (\( n = 19 \)), as were cases for which—besides ranitidine—antacids such as PPIs were coadministered (\( n = 18 \)). Scans from patients who received esomeprazole in addition to an oral PPI regimen were evaluated separately (\( n = 4 \)).

Of the 142 included patients, age varied between 0.5 and 51 y (mean, 11 y); 51% were male (\( n = 72 \)), and 49% were female (\( n = 70 \)). Unexplained abdominal pain, lower-intestine hemorrhage, or both were indications for admission. Ranitidine as a pretreatment procedure had been received by 117 patients. Nineteen of these received a dosage of 3 mg/kg or 150 mg orally 2 times daily starting 1 d before the scan. The other 98 received 1 mg/kg or 50 mg intravenously 15 min before the scan. Twenty-five patients were pretreated with a PPI, and 23 patients were treated with 10–40 mg of esomeprazole intravenously 30 min before the scan. Two patients who were on pantoprazole did not receive additional pretreatment. Four patients received esomeprazole, 10–40 mg intravenously, in addition to

### TABLE 1
Premedication Protocols Adjusted to Age and Weight

<table>
<thead>
<tr>
<th>Medication</th>
<th>1–12 y, &lt;20 kg</th>
<th>1–12 y, &gt;20 kg</th>
<th>&gt;12 y</th>
<th>Administration before scan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral ranitidine oral</td>
<td>3 mg/kg</td>
<td>3 mg/kg; maximum, 150 mg</td>
<td>150 mg</td>
<td>Twice daily, starting 1 d before scan; last dose, morning before scan</td>
</tr>
<tr>
<td>Intravenous ranitidine</td>
<td>1 mg/kg</td>
<td>1 mg/kg; maximum, 50 mg</td>
<td>50 mg</td>
<td>15 min before scan</td>
</tr>
<tr>
<td>Intravenous esomeprazole</td>
<td>10 mg</td>
<td>20 mg</td>
<td>40 mg</td>
<td>30 min before scan</td>
</tr>
</tbody>
</table>

### TABLE 2
Meckel Scan Quality After Antacid Pretreatment

<table>
<thead>
<tr>
<th>Observed ( ^{99m} )Tc-pertechnetate release</th>
<th>Oral ranitidine, 18–150 mg, ( n = 19 )</th>
<th>Intravenous ranitidine*, 5–62 mg, ( n = 98 )</th>
<th>Intravenous esomeprazole*, 10–40 mg, ( n = 23 )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent in duodenal and intestinal lumen</td>
<td>3</td>
<td>23</td>
<td>11</td>
</tr>
<tr>
<td>Activity in duodenal or intestinal lumen</td>
<td>3</td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>Activity in both duodenal and intestinal lumen</td>
<td>13</td>
<td>62</td>
<td>8</td>
</tr>
</tbody>
</table>

*Esomeprazole resulted in significantly better scan quality than intravenous ranitidine (\( P = 0.034 \)).
oral omeprazole 20–40 mg 1–2 daily or esomeprazole 20–40 mg 1–2 daily.

Each scan was assessed for the absence or presence of activity in the duodenal lumen, in the lumen of the intestine, or both (Table 2). Interobserver agreement was 92%, with a $\kappa$ of 0.83 for the assessment of intestinal $^{99m}$Tc release and 0.85 for the estimation of activity in the duodenum.

After oral administration of ranitidine (18–150 mg twice daily), starting the day before the scan and ending with the last dose on the morning before the scan, $^{99m}$Tc-pertechnetate release was absent in 3 of 19 (16%) patients, whereas 13 (68%) scans showed activity in both the duodenal and the intestinal lumen.

After patient preparation using intravenous ranitidine, 23 of 98 (23%) scans showed no released activity and 62 (63%) showed $^{99m}$Tc activity in both the duodenum and the intestinal lumen.

Eleven of the 23 scans (48%) obtained after intravenous esomeprazole showed no activity in the intestinal lumen, and 8 scans (35%) showed activity in both the duodenal and the intestinal lumen (Fig. 1). Absence of activity was seen significantly more often after intravenous esomeprazole premedication than after intravenous ranitidine ($P = 0.034$). When absence of activity in the duodenal and intestinal lumen was compared with activity in the duodenal or intestinal lumen, esomeprazole significantly more often showed absence of background noise caused by $^{99m}$Tc-pertechnetate excretion than did oral ranitidine ($P = 0.014$) or intravenous ranitidine ($P = 0.019$).

The scans of 2 patients who received solely pantoprazole as part of their standard-care treatment (without additional intravenous esomeprazole) showed activity in both the duodenum and the intestine. No luminal $^{99m}$Tc activity was observed in any of the 4 patients who received esomeprazole in addition to their standard-care PPI treatment.

The time lapse between esomeprazole administration and scan onset was recorded for 20 patients. Most frequently, pretreatment was administered 30 min before the start of scanning (48%). In another 6 patients (26%), scanning started within 45 min before administration of esomeprazole. Figure 2 shows $^{99m}$Tc activity in the duodenal or intestinal lumen after esomeprazole administration in relation to the time between administration and the start of the scan. The scans of patients who were treated outside the time window of 30–45 min showed $^{99m}$Tc-pertechnetate excretion in the duodenum, intestine, or both. In 9% ($n = 13$) of the patients, a Meckel diverticulum was detected. In all 13 patients, pathology confirmed the presence of ectopic gastric tissue.

DISCUSSION

After H2 blockers were recalled from the market in 2019, pretreatment with intravenous esomeprazole was implemented in our hospital because of its favorable pharmacokinetics, short time of onset, and well-established efficiency and safety in

![FIGURE 1. Examples of static images 30 min after injection. (A) Normal Meckel scan with adequate inhibition (arrow) of $^{99m}$Tc excretion. (B) The only unexpected hot spot (arrow) in abdomen was stasis of urine in prominent renal pelvis, as confirmed on posterior static image. (C) Accumulation of $^{99m}$Tc in gastric mucosa and minor excretion in duodenum. (D) Clear luminal activity in both duodenum and intestine.](image)

![FIGURE 2. Absence of $^{99m}$Tc activity release, activity detected in duodenal or intestinal lumen or both during Meckel scan, and time between esomeprazole administration and start of scan.](image)
children (8). Our study covering 10 y of Meckel scans showed that neither ranitidine nor esomeprazole could prevent all cases of 99mTc-pertechnetate release but that esomeprazole better suppressed activity release in the duodenum and the intestine (48% vs. 23%; P = 0.034). Interobserver agreement was excellent. The difference in performance between the H2 blocker and the PPIs can be explained by ranitidine’s lower potency as far as gastric acid inhibition is concerned (12,13). The effect of oral PPI pretreatment could not be evaluated since only one patient could be included. Moreover, an oral regimen 24–48 h before the scan may give rise to large variations, including interpatient differences in time between last administration of medication and start of scan, as well as malabsorption or low compliance, which can be expected in small children whose caretakers are responsible for administering oral medication. Intravenous administration of esomeprazole in patients who already require an intravenous cannula for 99mTc-pertechnetate is not considered a major intervention.

The fixed time of 30 min before esomeprazole administration was chosen on theoretic grounds and available pharmacokinetic data, but our results indicate that 30–45 min may be more practical. Our findings did not support a time exceeding 50 or 60 min, nor did we find evidence that starting the scan earlier than 30 min after PPI administration will lead to a scan of sufficient quality.

The prevalence of Meckel diverticulum in our population (9%) is consistent with earlier findings with a corresponding specificity of 100% in diagnosing ectopic gastric tissue (1,14).

Because of the unavailability of ranitidine, a head-to-head study design was not opportune. Thus, the next best design was a retrospective comparative study using documented data in which scans were simultaneously reassessed by 2 independent nuclear medicine physicians. Whether an oral regimen of omeprazole or pantoprazole medication would enhance the scan quality to a comparable extent cannot be concluded from our data (n = 2) or from the 4 patients who received intravenous esomeprazole premedication in addition to an oral PPI. Nevertheless, until more data are available, we recommend intravenous esomeprazole premedication 30–45 min before image acquisition along with antacid comedication, as adherence to any oral regimen is difficult to confirm and, moreover, no adverse effects are expected of a 1-time doubled dose of PPI (8).

CONCLUSION

Intravenous esomeprazole pretreatment outperforms ranitidine in inhibiting gastrointestinal release of 99mTc-pertechnetate during Meckel diverticulum scintigraphy. Additionally, intravenous administration of esomeprazole holds several advantages over oral administration, such as a fast onset of effect and applicability in small children.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

KEY POINTS

**QUESTION:** Is pretreatment using a PPI as effective as ranitidine in inhibiting gastrointestinal 99mTc-pertechnetate release in Meckel scan scintigraphy?

**PERTINENT FINDINGS:** Esomeprazole was found to suppress 99mTc-pertechnetate excretion comparably to ranitidine. The scan quality was significantly more often better using esomeprazole than ranitidine.

**IMPLICATIONS FOR PATIENT CARE:** The current findings will enable clinicians to replace—on the basis of scientific findings rather than theoretic assumptions—intravenous esomeprazole, 30–45 min before the scan, with ranitidine in patient preparation protocols.

REFERENCES